Stefano Grassani, Jul 27, 2012
On Jan. 11, 2012, the Italian Antitrust Authority (“IAA”) found Pfizer Inc. and its Swedish and Italian subsidiaries guilty of abuse of dominant position pursuant to Article 102 of the Treaty on the Functioning of the European Union. The IAA alleged that these subsidiaries jointly engaged in unlawful exclusionary conducts so as to unlawfully extend IP exclusive rights over Pfizer’s Xalatan blockbuster drug, deterring or, in any event, delaying e
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.191.5.239
Please verify email or join us to access premium content!